Drugs / F16IL2
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03207191 | Dec 2016 → Mar 2020 | acute myeloid leukemia | Philogen S.p.A. | Completed | No outcome recorded |
| Phase 1 | NCT02957032 | Apr 2016 → Sep 2023 | acute myeloid leukemia | Philogen S.p.A. | Terminated | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT05468294 | Mar 2017 → Dec 2021 | non-small cell lung carcinoma | Philogen S.p.A. | Unknown | No outcome recorded |
| Phase 1/2 | NCT01134250 | Aug 2008 → Apr 2014 | breast cancer, metastatic melanoma, non-small cell lung carcinoma | Philogen S.p.A. | Completed | No outcome recorded |
| Phase 1/2 | NCT01131364 | Jun 2008 → Mar 2012 | breast cancer | Philogen S.p.A. | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02054884 | Oct 2013 → Dec 2016 | cutaneous neuroendocrine carcinoma | Philogen S.p.A. | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | F16IL2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02957032 ↗ |
| Modality | Protein / enzyme biologic | “Tumour-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein” NCT01131364 ↗ |
| Route | Intravenous | “Intravenous (i.v.) infusions of F16IL2” NCT01131364 ↗ |
| Target | TNC | “Tenascin other” CHEMBL2109583 ↗ |